Atossa Therapeutics (ATOS) announced it has requested a Type C meeting with the U.S. Food and Drug Administration, FDA, to discuss a regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction. Atossa is a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and risk-reduction, commonly termed prevention of breast cancer.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics Receives Nasdaq Non-Compliance Notice
- Atossa selects PSI for Z-endoxifen monotherapy study
- Buy Rating for Atossa Therapeutics: Strong Financials and Promising Endoxifen Developments
- Atossa Therapeutics Advances Breast Cancer Treatments
- Positive FDA Feedback and Promising Phase 2 Results Justify Buy Rating for Atossa Therapeutics